Skip to content
EmergingResearch compoundReference only

Hydrafinil

Wakefulness-promoting research chemical (9-fluorenol) from Cephalon's next-generation modafinil program. Weak, selective DAT inhibitor; preclinical data only, reference-only.

NootropicEugeroicEugeroicWakefulnessFocusDopamineAnti-fatigue

Pharmacology

ClassEugeroic · Wakefulness · Focus
Primary targetDopamine transporter (DAT), weak inhibitor
Targets2 receptor targets
Half-lifeN/A (not characterized in humans)
OnsetN/A (not characterized)
EvidenceReference only
Affected systemsDopamineAnti-fatigue

Contents

WHAT IS HYDRAFINIL?

Detailed overview

Hydrafinil (9-fluorenol) is a eugeroic research chemical from the fluorene family, identified by Cephalon during its search for a next-generation modafinil successor. It acts as a weak, relatively selective dopamine reuptake inhibitor and, in sleep-deprived mice, promoted wakefulness at doses roughly 39% more potent than modafinil per weight. Human clinical data are essentially absent, so it remains an unapproved research chemical sold in a legal grey area. This entry is educational and reference-only, reflecting the thin, mostly preclinical evidence base.

Mechanism

Weak DAT inhibitor (DRI)

Half-life

Not characterized in humans

Onset

Not characterized (dose early in day)

Legal status

Unapproved research chemical

Evidence

Preclinical only (reference-only)

Receptor profile

  • Dopamine transporter (DAT)Weak
  • Wake-promoting (modafinil-like) circuitsWeak

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • Headache (anecdotal, limited data)
  • Nausea
  • Insomnia, sleep disruption from late or excessive dosing
  • Anxiety, restlessness (anecdotal, dopaminergic)
  • Unknown long-term safety (no human safety studies)

Contraindications · 5

  • No human safety data: avoid during pregnancy and breastfeeding
  • Cardiovascular disease (theoretical dopaminergic/stimulant load, unstudied)
  • Psychiatric conditions (anxiety, psychosis history): dopaminergic caution
  • Combining with other stimulants or wakefulness agents (additive load)
  • Competitive athletes: uncertain WADA status (S6 catch-all risk)

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Wakefulness-promoting research chemical (9-fluorenol) from Cephalon's next-generation modafinil program. Weak, selective DAT inhibitor; preclinical data only, reference-only.

Telegram

Have a question about Hydrafinil?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC13H10O
UpdatedJuly 9, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: July 9, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.